Axcelis Technologies (ACLS) Tops Q2 EPS by 10c

Axcelis Technologies (NASDAQ: ACLS) reported Q2 EPS of $0.55, $0.10 better than the analyst estimate of $0.45. Revenue for the quarter came in at $147.3 million versus the consensus estimate of $137.27 million.

GUIDANCE:

Axcelis Technologies sees FY2021 revenue of $625 million, versus the consensus of $557 million.

For earnings history and earnings-related data on Axcelis Technologies (ACLS) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c